Abstract: Provided is an herbal composition including an extract from an herbal raw material including at least one of Artemisia argyi, Ohwia caudata, Anisomeles indica (L.) O. Ktze, Ophiopogon japonicus, Houttuynia cordata, Platycodon grandiflorus, Glycyrrhiza uralensis, Perilla frutescens, and chrysanthemum. Also provided is a method for preparing the herbal composition and a method for preventing or treating a viral infection by administering an effective amount of the herbal composition to a subject in need thereof.

Abstract: Method of preventing or treating coronaviruses, such as COVID-19 infection, in a subject, comprising administering to the subject an effective amount of thymoquinone, such as an effective amount of black seed oil.

Abstract: The invention concerns pharmaceutical and nutritional compositions comprising hawthorn fruit (shan za), or an active fraction extracted therefrom, for the treatment or alleviation of symptoms of anxiety disorders, stress, or depression.

Abstract: The present invention relates to a composition for hangover relief, comprising a noni fruit extract or a fraction thereof, and more specifically provides a noni fruit extract or a fraction thereof, which is prepared using a certain concentration of ethanol as an extraction solvent, to contain a large amount of polysaccharides having excellent hangover relieving functionality and an average molecular weight of 8 kDa to 10 kDa.

Abstract: An antibiotic composition and a method of preparing the same are disclosed which comprises: a mixture of liquid fruits and spices having antimicrobial properties at predetermined concentration ratio, all undergone an anoxic fermentation process without being exposed to sunlight for a predetermined period of time and at a predetermined temperature so that the antibiotic composition is characterized by having antimicrobial activities and polyphenol bioavailability.

Abstract: A composition for preventing, ameliorating or treating an androgen-dependent disorder includes Phyllostachys pubescens extract as an effective component. It was found that, compared to the extracts of other types of bamboo, the Phyllostachys pubescens extract of the present invention can significantly reduce the expression amount of the SRD5A2 gene which encodes 5?-reductase while hardly showing any cytotoxicity. The composition of the present invention was found to have effects that can reduce the prostate weight, reduce the proliferation of epithelial cells in prostate tissues, and also can reduce the content of testosterone, dihydrotestosterone, PSA, and SRD5A2 in blood serum. Thus, the composition of the present invention can be advantageously used for an androgen-dependent disorder.

Abstract: The present disclosure relates to the use of CuPTSM in methods and compositions for treating subjects with a neurodegenerative disease. Subjects with a neurodegenerative disease can have, e.g., amyotrophic lateral sclerosis (ALS).

Abstract: Compositions and methods for skincare treatment are provided. The invention relates more generally to skin care treatment and more particularly, to compositions and methods for promoting healthy skin, skin regeneration, skin repair, skin bed preparation, and enhanced wound healing.

Abstract: The invention provides a peptide, or a derivative or analogue thereof, or a nucleic acid encoding the peptide, or a derivative or analogue thereof, for use in treating, preventing or ameliorating a coronavirus infection or symptoms in an infected subject.

Abstract: The invention relates generally to biotechnology and medicine and to sources and salts of autophagy inhibiting peptides useful as pharmaceutical compounds. In particular, the invention provides method for reducing formyl-peptide-receptor (FPR) mediated p38 MAPK kinase activity of cells comprising providing said cells with a source of amino acids said source comprising at least 50%, more preferably at least 75%, most preferably at 100% amino acids selected from the group of autophagy inhibiting amino acids alanine (in one letter code: A), glutamine (Q), glycine (G), valine (V), leucine (L), proline (P), and arginine (R).

Abstract: A drug composition contains an effective amount of a drug active containing a polymyxin, an effective amount of otilonium bromide, and a pharmaceutically-acceptable carrier. A method for treating or protecting against a Gram-negative infection containing the step of administering a drug composition, a disinfecting composition similar to the drug composition, and an adjuvant for a drug active also may contain otilonium bromide.

Abstract: The present invention relates to use of the compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof in the manufacture of a medicament or pharmaceutical composition for preventing, treating or lessening POD,

Abstract: The invention relates to cyclosporine formulations for use in the prevention or treatment of pulmonary chronic graft rejection. In particular, the invention provides a cyclosporine liquid formulation for use as an aerosol for inhalation in a method of preventing or treating pulmonary chronic graft rejection in single lung transplanted patients. The formulation is preferably administered once or twice daily. The formulation may be aerosolized with a nebulizer that comprises features for monitoring the time, date and duration of inhalation by the patient, in order to monitor patient adherence. The formulation according to the invention may be combined with standard immunosuppressants and corticosteroids.

Abstract: Methods are provided for the prevention of aggregation, simple purification stabilization and preservation of phage preparations for the use of treating bacterial infections.

Abstract: The present invention is related to T cell epitopes and methods of their use, in particular bystander proteins, and identification of peptides which may be used to stimulate a CD8+ cytotoxic T cell response, as well as peptides which stimulate a CD4+ helper T cell response to the cells carrying the proteins.

Abstract: The present invention relates to a protein and polypeptide for use in promoting wound healing. It further relates to a nucleic acid molecule encoding the protein or polypeptide of the invention, an expression vector comprising said nucleic acid molecule, and a host cell comprising said expression vector.

Abstract: The present disclosure provides compositions and methods of treating motor neuron diseases, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). A modulator of a heat shock protein, such as an Hsp70 family member protein, may be used in the present method. Alternatively, a mutant heat shock protein may be used.

Abstract: The present disclosure is directed to methods and compositions for inhibiting a cancer cell using nucleic acid sequences encoding elephant p53 or elephant p53 amino acid sequences.

Abstract: The present invention relates to a use of a cell adhesion molecule-related/down-regulated by oncogene (Cdo) protein or a gene encoding the same for preventing or treating neuromuscular diseases caused by damage to motor neurons, particularly muscle stem cells and neuromuscular junctions, due to aging, oxidative stress, and the like; and a method for screening for candidates for activating the expression of Cdo. When Cdo is deleted in motor neurons or neuromuscular junctions, aggravation of damage to degenerative motor neurons due to aging, and DNA damage caused by oxidative stress and inflammation are caused, which may cause neuromuscular diseases. Thus, the diseases can be treated through overexpression and activity of the Cdo protein and the gene encoding the same.

Abstract: The present disclosure relates, inter alia, to compositions and methods, including chimeric proteins that find use in the treatment of disease, and to detection and treatment of drug resistant cancer using chimeric proteins.

Abstract: Disclosed herein is a topical pharmaceutical composition for promoting wound healing, comprising: a therapeutically effective amount of a polypeptide of SEQ ID NO. 1 or 2, or a derivative or analog thereof, and a pharmaceutically acceptable carrier.

Abstract: The invention disclosed herein provides methods and materials useful in gene therapy regimens designed to treat creatine deficiency disorders. Creatine deficiency disorders are inborn errors of creatine metabolism, an energy homeostasis molecule. One of these, guanidinoacetate N-methyltransferase (GAMT) deficiency, has clinical characteristics that include features of autism, self-mutilation, intellectual disability and seizures with approximately 40% having a disorder of movement; failure to thrive can also be a component. As disclosed herein, a gene therapy approach can result in long-term normalization of GAA with increased creatine in guanidinoacetate N-methyltransferase deficiency and at the same time resolves the behavioral phenotype in a murine model of the disorder. These findings have important implications for the development of a new therapy for this abnormality of creatine metabolism.

Abstract: The disclosure provides compositions and methods for the treatment and/or prevention of sickle cell disease.

Abstract: The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.01% (w/w) phenol, their preparation, kits comprising such compositions as well as uses thereof.

Abstract: The invention relates to pharmaceutical compositions comprising a first type of granules and a second type of granules, wherein said first type of granules comprises a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and no GLP-1 peptide, and wherein said second type of granules comprises a GLP-1 peptide and no salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, as well as the intermediate granules, processes for the preparation of the granules and compositions, and use thereof in medicine.

Abstract: Certain embodiments are directed to methods for treating, ameliorating, or preventing exercise-induced or exercise-associated hypoglycemia comprising administration to a subject in need thereof a formulation(s) of glucagon or glucagon analog in an amount effective to treat, ameliorate, or prevent the condition. The subject can be administered a glucagon or a glucagon analog composition 1, 5, 10, 15 to 20, 25, 30 minutes prior to initiation of exercise.

Abstract: The present invention relates to oral therapy of a subject suffering from disease e.g. polycystic disease e.g. polycystic kidney disease or polycystic liver disease or PCOS or hypotension especially neurogenic orthostatic hypotension and postprandial hypotension, or intractable diarrhea or neuroendocrine tumors or carcinoid syndrome. The method of treatment comprises oral administration to the subject of a therapeutically effective amount of an oral somatostatin receptor ligand (SRL) e.g. oral octreotide. Combination therapy of oral SRLs with other drugs is also envisaged, e.g. octreotide in combination with a therapeutically effective amount of a second therapeutic agent and optionally in combination with a therapeutically effective amount of a third therapeutic agent.

Abstract: The present invention is in the fields of medicinal chemistry, biotechnology and pharmaceuticals. The invention provides compositions comprising one or more collagen mimetic peptides, optionally attached to one or more therapeutic compounds or one or more imaging compounds, methods for use of such compositions in treating, preventing, ameliorating, curing and/or diagnosing certain diseases and physical disorders in humans and veterinary animals, including anterior segment ocular diseases and physical disorders, including corneoscleral diseases, disorders or conditions such as myopia, presbyopia, keratoconus and the like. The invention also provides the use of such compositions in treating, preventing, ameliorating, curing and/or diagnosing diseases, disorders and conditions in a variety of other tissues, organs and organ systems. The invention also provides methods of manufacturing such collagen mimetic peptides and compositions.

Abstract: This invention is in the field of medicinal pharmacology. In particular, the present invention relates to pharmaceutical compositions capable of preventing, treating and/or ameliorating symptoms related to conditions caused by the SARS-CoV-2 vims (e.g., COVID-19). The invention further relates to methods of preventing, treating and/or ameliorating symptoms related to conditions caused by the SARS-CoV-2 vims (e.g., COVID-19), comprising administering to a subject (e.g., a human patient) a pharmaceutical composition comprising lactoferrin, S1RA, entecavir, lomitapide, metoclopramide, bosutinib, thioguanine, fedratinib, Z-FA-FMK, amiodarone, verapamil, gilteritinib, clofazimine, niclosamide, and remdesivir (alone or with additional agents).

Abstract: The present disclosure provides an application of RNA-dependent RNA polymerase (RDR) in treatment of cell proliferative diseases. The RDR can be widely used for inhibiting cell proliferation, apoptosis and migration of various tumors, thereby providing a new choice for clinical treatment of tumors.

Abstract: A co-therapeutic regimen comprising AAV9-mediated intrathecal/intracisternal and/or systemic delivery of an expression cassette containing a hIDS gene and two or more immunosuppressants is provided herein. Also provided are methods and kits containing these vectors and compositions useful for treating Hunter syndrome and the symptoms associated with Hunter syndrome.

Abstract: Methods of treating superficial digital flexor tendon injuries, deep and superficial muscle/tendon contracture, navicular syndrome, and suspensory ligament inflammation and injuries in the limb of a quadruped animal, such as hooved animals and other quadrupeds. Such abnormalities may be inflammatory or associated with pain. The abnormalities may be chronic or acute. Such abnormalities may involve anatomical structures a limb, neck, torso, and/or pelvis of the quadruped animal.

Abstract: Methods of reversing hyperglycemia and suppressing diabetes onset in a patient at risk of developing type 1 diabetes are provided. In particular, a vector system comprising a first expression cassette encoding BCL2 associated X apoptosis regulator (BAX) and a hypermethylated second expression cassette encoding a secreted glutamic acid decarboxylase 65 (sGAD55) are administered to the patient to induce a tolerogenic response.

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

Abstract: Systems and methods are presented that allow for selection of tumor neoepitopes that are then used to generate recombinant nucleic acids that encode one or more polytopes that are optimized for proper trafficking and processing. In preferred methods, the polytopes are encoded in a plasmid and/or a viral expression system for use as a therapeutic agent.

Abstract: The invention relates to methods for producing an RSV F protein trimer in a fed batch cell culture.

Abstract: This invention relates to genetically modified gram-negative bacteria specifically designed to release engineered Outer Membrane Vesicles (OMVs) carrying Coronavirus (poly)peptides. The invention further provides methods for the preparation of the OMVs, immunogenic compositions containing them and the use thereof as vaccines for the prophylaxis and treatment of SARS-CoV2 infections.

Abstract: The present disclosure provides a glycoengineered SARS-CoV-2 spike protein which is capable of eliciting an enhanced immune response relative to a native spike protein of SARS-CoV-2 and its variants. The glycoengineered spike protein exposes the glycosylation sites and at the same time preserves the tertiary structure of the spike protein. The present disclosure therefore provides improved immunogens, vaccines, and methods for better prevention and treatment of the emerging coronavirus infections.

Abstract: Provided are novel vaccines for prophylactic treatment of SARS-CoV-2 infections and COVID-19 and methods of making the vaccines.

Abstract: The present invention disclosed an intradermal vaccine that protects against Middle East Respiratory Syndrome coronavirus (MERS-CoV). In one embodiment, the vaccine is a DNA vaccine. In one embodiment, the vaccine comprises an antigen. The antigen can be a consensus antigen. The consensus antigen can be a consensus spike antigen. The present invention also discloses methods of treating or preventing MERS-CoV in a subject in need thereof by administering the vaccine intradermally to the subject.

Abstract: Provided are a DNA vaccine against SARS-CoV-2 virus infection in a subject which comprises a codon optimized polynucleotide sequence encoding a polypeptide of the SARS-CoV-2 virus. Also provided are a vaccine combination against SARS-CoV-2 vims infection, which comprises said DNA vaccine and an antigen peptide vaccine. The vaccine combination is able to confer a full protection against the SARS-CoV-2 vims infection in NHP studies.

Abstract: The present disclosure provides recombinantly manufactured fusion proteins comprising a SARS-CoV-2 Receptor Binding Domain (SARS-CoV-2-RBD) fragment or an analog thereof linked to a human Fc fragment for use in relation to the 2019 Novel Coronavirus (COVID-19). Embodiments include the administration of the fusion proteins to patients that have recovered from COVID-19 as a booster vaccination, to antibody naïve patients to produce antibodies to the SARS-CoV-2 virus to enable the patients to become convalescent plasma donors, to patients who have been infected by the SARS-CoV-2 virus and have contracted COVID-19 in order to limit the scope of the infection and ameliorate the disease, and as a prophylactic COVID-19 vaccine. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

Abstract: The present disclosure provides compositions for the prevention and treatment of genital herpes, comprising nucleoside-modified RNAs that encode herpes simplex virus (HSV) glycoproteins, including those involved in virus entry and immune evasion, and methods of use thereof.